CA2693594A1 — Cyclic amine substituted pyrimidinediamines as pkc inhibitors
Assigned to Rigel Pharmaceuticals Inc · Expires 2009-01-22 · 17y expired
What this patent protects
The invention encompasses Pyrimidine compounds and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.
USPTO Abstract
The invention encompasses Pyrimidine compounds and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.